Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 651 - 700 out of 10,129

Document Document Title
WO/2008/097546A3
Compounds that inhibit cholinesterase activity and, upon hydrolysis release a pharmacologically active agent. The pharmacologically active agent obtained by hydrolysis of the compound can treat, for example, a nervous system condition, a...  
WO/2008/096094A1
Representatives of compounds of formula (I) having M3 receptor antagonist activity; a composition comprising such a compound; the use of such a compound in therapy (such as asthma or COPD); and a method of treating a patient with such a ...  
WO/2008/083967A2
The present invention relates to pyrrolidin-2-ones according to the formula (1), or salts thereof, wherein R1 is hydrogen or a nitrogen protecting group, methods for their preparation and their use in the preparation of NEP-inhibitors, p...  
WO/2008/083967A3
The present invention relates to pyrrolidin-2-ones according to the formula (1), or salts thereof, wherein R1 is hydrogen or a nitrogen protecting group, methods for their preparation and their use in the preparation of NEP-inhibitors, p...  
WO/2008/084086A1
The present invention relates to a method for the production of o-vinylcarbamates or vinylcarbonates, wherein a secondary amine or an alcohol is reacted with an alkyne compound in the presence of a catalyst selected from among carbonyl c...  
WO/2008/082881A1
Di-, tri-, and/or tetra-(meth)acryloyl-containing materials and compositions are provided. Such materials and compositions can preferably be hardened, without undue shrinkage, to provide hardened materials and/or compositions with proper...  
WO/2008/081041A3
Rivastigmine hydrogentartrate in amorphous form or in a crystalline form characterized by an X-ray powder diffraction pattern exhibiting peaks at 2Θ values of 5.1, 14.7, 16.5, 17.6, 18.6, 20.4, 21.1° ± 0.2° (Form I), or 2Θ values of...  
WO/2008/081041A2
Rivastigmine hydrogentartrate in amorphous form or in a crystalline form characterized by an X-ray powder diffraction pattern exhibiting peaks at 2Θ values of 5.1, 14.7, 16.5, 17.6, 18.6, 20.4, 21.1° ± 0.2° (Form I), or 2Θ values of...  
WO/2008/066900A1
This invention is directed to compounds of formula (I), where G is -O-, -S-, -C(g1)(g2)-, or -NH-, and n = 1, 2, or 3. Such compounds modulate potassium channels. The compounds are useful for the treatment and prevention of diseases and ...  
WO/2008/062859A1
A process for the production of phenylalanine derivatives having quinazolinedione rings as represented by the general formula (1) or pharmaceutically acceptable salts thereof:(1) which comprises the following steps (a), (b) and (c): the ...  
WO/2008/059051A1
The invention relates to a process for the production of an imide (1) (2) (3) via the enantioselective addition of an amine (2) to an alkene (3) wherein Y is OR, wherein R is alkyl or Bn, said process comprising: incubating Pd(OTf)2 with...  
WO/2008/059299A1
The invention relates to chiral cyclic β-amino acids of Formula (I) and their salts formed with pharmaceutically acceptable acids or bases, wherein the main meanings of the substituents are as follows: R stands for C1-4 Alk; X stands fo...  
WO/2008/059953A1
Disclosed is a method for stably producing an isocyanate with high yield for a long time without using phosgene. This method for producing an isocyanate does not cause the problems involved in the prior art. Specifically disclosed is a m...  
WO/2008/054233A3
The process for preparation of docetaxel consists in that the hydroxyl groups at C-7 and C-IO position of 10- deacetylbaccatin III and the amino group of (4S,5R)-2- methoxyphenyl-4-phenyl-l, 3-oxazolidine-5-carboxylic acid are protected ...  
WO/2008/054233A2
The process for preparation of docetaxel consists in that the hydroxyl groups at C-7 and C-IO position of 10- deacetylbaccatin III and the amino group of (4S,5R)-2- methoxyphenyl-4-phenyl-l, 3-oxazolidine-5-carboxylic acid are protected ...  
WO/2008/052788A1
The compounds and the synthesis of [F-18]-labeled L-glutamic acid, [F-18]-labeled L-glutamate, derivatives thereof of the formula (I) and uses thereof are described.  
WO/2008/046889A1
The invention relates to an insect- and mite-repelling agent, characterized by a content of at least one substituted, enantiomer-enriched α-,ω-amino alcohol derivative of formula (1) wherein X represents hydrogen, COR11 or R13, R13 rep...  
WO/2008/048373A3
Compositions and methods for altering protein degradation by the 20S proteasome are provided. Screening assays for identifying compounds that modulate protein degradation are provided. Methods of treating disorders by modulating protein ...  
WO/2008/045391A3
The present invention relates to a novel crystal of (S)-(+)-2-(2-chlorophenyl)-2- hydroxy-ethyl carbamate, pharmaceutical compositions comprising this crystal and, and methods of making and using this crystal.  
WO/2008/045391A2
The present invention relates to a novel crystal of (S)-(+)-2-(2-chlorophenyl)-2- hydroxy-ethyl carbamate, pharmaceutical compositions comprising this crystal and, and methods of making and using this crystal.  
WO/2008/044731A1
Disclosed is a compound represented by the general formula (I) below, which has a plasminogen activator inhibitor-1 (PAI-1) inhibitory activity, a salt thereof, or a hydrate or solvate of any of them. (I) (In the formula, R1 represents a...  
WO/2008/043798A1
A process for the preparation of for the preparation of β-amino aldehydes and derivatives thereof, in particular β-amino acids and Υ-amino alcohols, by reacting carbamate-protected imines and unmodified aldehydes in the presence of an...  
WO/2008/042896A3
Disclosed are nordihydroguaiaretic acid derivative compounds including various end groups bonded by a carbon atom or heteroatom though a side chain bonded to the respective hydroxy residue O groups by an ether bond or a carbamate bond, p...  
WO/2008/039367A1
The present invention concerns methods of synthesis of trans-tert-butyl-2- aminocylcopentylcarbamate comprising contacting 6-tosyl-6-azabicyclo[3.1.0]hexane with TMSN3 and TBAF to produce 2-azido-N-tosylcyclopentananiine; reducing the 2-...  
WO/2008/037433A1
The invention relates to a process for making the compound of general formula (I), or an acid addition salt wherein the dotted line indicates a carbon-carbon bond on the asymmetric carbon, which process comprises the steps of a) the reac...  
WO/2008/037503A2
The invention relates to a process for making the compound of general formula (I), or an acid addition salt wherein the dotted line indicates a carbon-carbon bond on the asymmetric carbon, which process comprises the steps of a) the reac...  
WO/2008/037503A3
The invention relates to a process for making the compound of general formula (I), or an acid addition salt wherein the dotted line indicates a carbon-carbon bond on the asymmetric carbon, which process comprises the steps of a) the reac...  
WO/2008/033328A3
The present invention provides conformationally-defined macrocyclic compounds that bind to and/or are functional modulators of the motilin receptor including subtypes, isoforms and/or variants thereof. These macrocyclic compounds, at a m...  
WO/2008/034119A3
The present invention provides polymeric delivery systems including hindered ester moieties. Methods of making the polymeric delivery systems and methods of treating mammals using the same are also disclosed.  
WO/2008/028845A1
The instant invention relates to a composition comprising a) an organic material which is susceptible to oxidative, thermal or light-induced degra- dation, and b) at least one compound of the formula (I) wherein the general symbols are a...  
WO/2008/026678A1
Disclosed is a process for producing an optically active succinic acid imide derivative (3) which is a key intermediate for the production of ranirestat. The derivative (3) can be produced readily by treating a succinic acid diester deri...  
WO/2008/022976A1
Pharmacological inhibition of fatty acid amide hydrolase (FAAH) activity leads to increased levels of fatty acid amides. The alkylcarbamic acid aryl ester of Formula (I), KDS-4103, is a FAAH inhibitor. Described herein is a process for t...  
WO/2008/022938A1
The present invention relates to compounds of the general Formula (I) wherein (A) is a 5 or 6-membered aromatic or heteroaromatic ring; R1 is cycloalkyl or is aryl or heteroaryl, wherein at least one ring is aromatic in nature, unsubstit...  
WO/2008/020452A1
The present invention relates to an improved process for preparation of Rivastigmine of formula (I) or pharmaceutically acceptable salts thereof comprising a step of N-methylation of compound of formula (III), wherein R1 = R2 = H or R1 =...  
WO/2008/015240A1
The present invention is related to a family of N-phenyl-prenylamine derivatives of formula (I), and to their use in the treatment of cognitive, neurodegenerative or neuronal diseases or disorders, such as Alzheimer's disease or Parkinso...  
WO/2008/013860A3
Acyloxyalkyl carbamate prodrugs of α-amino acids, pharmaceutical compositions thereof, methods of making acyloxyalkyl carbamate prodrugs of α-amino acids and methods of using acyloxyalkyl carbamate prodrugs of α-amino acids, and pharm...  
WO/2008/013269A1
Disclosed is an isoquinuclidine derivative which enables to easily synthesize oseltamivir or an analogue thereof. Specifically disclosed is an isoquinuclidine derivative represented by the formula (1) below or a mirror image structure of...  
WO/2008/013860A2
Acyloxyalkyl carbamate prodrugs of α-amino acids, pharmaceutical compositions thereof, methods of making acyloxyalkyl carbamate prodrugs of α-amino acids and methods of using acyloxyalkyl carbamate prodrugs of α-amino acids, and pharm...  
WO/2008/010897A3
Disclosed is a method for preparing a compound of Formula 1 by contacting compound of Formula 2 with R1-NH2 in the presence of a carboxylic acid and a method for preparing a compound of Formula 2 by contacting a compound of Formula 4 wit...  
WO/2008/009897A1
The invention relates to the preparation of pregabalin and its opposite enantiomer, or a pharmaceutically-acceptable salt of either thereof, and to the intermediates used for their preparation.  
WO/2008/007670A1
A process for the production of a compound having a primary, secondary or tertiary aminomethyl-aromatic ring, characterized in that a fluoroboron compound represented by the formula (I): Ra(Rb)N-CH2-BF3M (I) or a dimmer thereof or a solv...  
WO/2008/004798A1
Disclosed herein are an HIF-1 inhibitor, a method for the preparation thereof, and a pharmaceutical composition comprising the same as an active ingredient The HIF-1 inhibitor shows anticancer activity thanks to the inhibition activity a...  
WO/2008/004798A8
Disclosed herein are an HIF-1 inhibitor, a method for the preparation thereof, and a pharmaceutical composition comprising the same as an active ingredient The HIF-1 inhibitor shows anticancer activity thanks to the inhibition activity a...  
WO/2008/003079A1
This invention is related to compositions and methods pertaining to PNA oligomers comprising one or more guanidinium moieties.  
WO/2007/147163A2
A method for synthesizing intermediates for use in the synthesis of carotenoid synthetic intermediates, carotenoid analogs, and/or carotenoid derivatives. The carotenoid analog, derivative, or intermediate may be administered to a subjec...  
WO/2007/147163A3
A method for synthesizing intermediates for use in the synthesis of carotenoid synthetic intermediates, carotenoid analogs, and/or carotenoid derivatives. The carotenoid analog, derivative, or intermediate may be administered to a subjec...  
WO/2007/141423A1
The invention concerns phenoxy-isobutyric acid derivatives of general formula (I) wherein: R1 and R2 are H, an alkyl group, or a -OR group where R is an alkyl, or R1 and R2 together form a hydrocarbon ring of 3 to 6 carbon atoms; R3 is H...  
WO/2007/134971A1
The invention relates to benzoyl-substituted alanines of formula (I), in which the variables R1 to R13 are defined as cited in the description, and to their agriculturally useful salts. The invention also relates to methods and intermedi...  
WO/2007/136323A1
The present invention relates to a process for the production of a compound of formula (I) comprising a reduction of the carboxyl and cyanide groups of a compound of formula (III), followed by resolvation of the racemic product into the ...  
WO/2007/132277A1
The compounds of the general Formula (I), wherein R1 is aryl or alkyl; R2 represents alkyl; R3 represents alkyl or aralkyl, are valuable pharmaceutical intermediates, which can be prepared by reacting a compound of the general Formula (I...  

Matches 651 - 700 out of 10,129